CLINICAL_TRIALS
trial_result
· 2021-07-01
Clinical Trial Update: A Study of MRX2843 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia [Phase 1, Phase 2]
Summary
Clinical trial update for MRX2843 in relapsed/refractory acute myeloid leukemia (Phase 1/Phase 2) with unknown status.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Betta Pharmaceuticals Co., Ltd. | Conditions: Acute Myeloid Leukemia Leukemia | Phase 1, Phase 2 | Status: UNKNOWN